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background:  Self-expanding transcatheter aortic valve replacement (TAVR) is superior to medical therapy for extreme risk pts with severe 
native valve aortic stenosis (AS). Its use in pts with low-gradient (LG) AS has not been prospectively studied.
methods:  The CoreValve US Expanded Use Study (EUS) was a prospective, non-randomized, single-arm study that evaluated the safety 
and effectiveness of TAVR and included extreme risk pts with LG AS, defined as mean gradient < 40 mmHg and peak velocity < 4 m/sec. 
Group A included pts with LG and resting LVEF ≥ 50%; Group B included pts with LG and resting LVEF < 50% (w/out dobutamine gradient 
augmentation). These results were compared with pts enrolled in the US Extreme Risk Pivotal Trial: Group C: LG and resting LVEF < 
50% (with dobutamine gradient augmentation), and Group D: mean gradient ≥ 40 mmHg or peak velocity ≥ 4 m/sec. Early outcomes were 
assessed by all-cause mortality or major stroke rate at 30 days.
results:  141 pts with attempted implant were enrolled from Dec 2012-Mar 2014 in EUS (Group A and B). Pts were elderly (82.3 ± 
8.6years), commonly men (61.1%) and 90.3% were New York Heart Association class III or IV. The STS PROM was 10.1 ± 5.3%. 
CoreValve diameters included 26 mm (21.0 %), 29 mm (40.6 %), and 31 mm (37.8 %).
Group A Group B Group C Group D
N = 99 N = 42 N = 66 N= 550
Annular diameter, mm 24.5 ± 2.3 25.8 ± 2.1 25.3 ± 1.7 24.0 ± 2.5
Pre-mean gradient mmHg1 29.7 ± 4.6 25.0 ± 5.0 28.9 ± 6.2 50.8 ± 14.0
30-day mortality or major stroke, % 11.2 19.3 21.2 9.6
30-day mortality, % 9.2 19.3 16.7 8.0
30-day major stroke, % 2.1 0.0 7.7 3.0
1resting mean gradient without dobutamine augmentation. Site reported for Group A/B and core lab reported for Group C/D.
Conclusion:  Early outcomes after TAVR in extreme risk pts with LG AS and preserved LVEF were similar to those in pts with high gradient 
AS; early event rates were higher in pts with LG AS and reduced LVEF, and were not predicted by dobutamine gradient augmentation.
